Rheumatology · Riverside, CA
NPI
1013991041
Since 2005
Specialty
Rheumatology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6180 Brockton Ave Ste 204
Riverside, CA, 92506
Phone (951) 781-7700
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
75,667 services
Medicare patients, 2024
399
Average age 73
Drug cost, 2024
$8.1M
8,104 prescriptions
Company payments, 2025
$814
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Babak Zamiri was code J1010 (injection, methylprednisolone acetate, 1 mg), 17,452 times for 125 patients. In total Babak Zamiri billed 75,667 services in 43 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-07-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 17,452 | 125 | $0.10 | $1,774 |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 12,394 | 14 | $8.59 | $106K |
| J0897 Injection, denosumab, 1 mg | Office | 8,771 | 138 | $20.44 | $179K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 5,628 | 22 | $24.88 | $140K |
| Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | Office | 1,993 | 12 | $9.75 | $19K |
| 99214 Office E&M - Established | Office | 890 | 330 | $100.98 | $90K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 589 | 273 | $13.24 | $7,799 |
| 96401 Chemotherapy Administration | Office | 359 | 150 | $61.56 | $22K |
| 96413 Chemotherapy Administration | Office | 343 | 63 | $112.26 | $39K |
| 96375 Injection Administration | Office | 298 | 58 | $12.95 | $3,858 |
| 96415 Chemotherapy Administration | Office | 286 | 42 | $24.25 | $6,937 |
| J1720 Injection, hydrocortisone sodium succinate, up to 100 mg | Office | 282 | 50 | $14.40 | $4,060 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 223 | 42 | $0.64 | $142 |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 209 | 19 | $57.62 | $12K |
| 20611 Joint Injection | Office | 178 | 50 | $123.42 | $22K |
By year: 2022 $1.1M for 53,902 services; 2023 $1.3M for 61,910 services; 2024 $1.2M for 75,667 services.
Medicare prescription drug claims, 2024
In 2024, the drug Babak Zamiri prescribed most often to Medicare patients was Prednisone, with 1,013 prescriptions and refills. In total Babak Zamiri wrote 8,104 Medicare prescriptions that cost $8.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 1,013 | 2,183 | 283 | $6,622 |
| Baclofen Generic | 970 | 2,513 | 341 | $18K |
| Hydroxychloroquine Sulfate Generic | 861 | 2,307 | 244 | $49K |
| Meloxicam Generic | 710 | 1,965 | 251 | $4,716 |
| Gabapentin Generic | 519 | 1,443 | 185 | $13K |
| Methotrexate Methotrexate Sodium | 481 | 1,249 | 139 | $17K |
| Sulfasalazine Generic | 357 | 909 | 113 | $14K |
| Folic Acid Generic | 249 | 709 | 73 | $1,854 |
| Diclofenac Sodium Generic | 228 | 339 | 70 | $7,616 |
| Leflunomide Generic | 213 | 536 | 70 | $16K |
| Prolia Denosumab | 201 | 1,198 | 122 | $325K |
| Alendronate Sodium Generic | 195 | 483 | 64 | $1,696 |
| Humira(Cf) Pen Adalimumab | 178 | 199 | 26 | $1.4M |
| Enbrel Sureclick Etanercept | 133 | 139 | 17 | $1.0M |
| Omeprazole Generic | 118 | 344 | 42 | $1,848 |
Brand drugs: - claims; generic drugs: 6,629 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Babak Zamiri $814 ($814 in general payments such as food, travel and fees) from 9 companies. The largest payer was Amgen Inc. with $310.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 21 | $310 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $125 |
| GlaxoSmithKline, LLC. GSK | 5 | $116 |
| Janssen Biotech, Inc. JNJ | 2 | $91.92 |
| ANI Pharmaceuticals, Inc. ANIP | 3 | $67.62 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $38.55 |
| UCB, Inc. UCB.BR | 1 | $25.98 |
| Abbvie Inc. ABBV | 1 | $20.28 |
| Tonix Medicines, Inc. | 1 | $19.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.